<DOC>
	<DOCNO>NCT00000872</DOCNO>
	<brief_summary>This trial test safety effectiveness early use combination anti-HIV drug HIV-infected infant young child effort block virus growth preserve normal immune function . Various anti-HIV drug combination need test order find best way treat infant child infect HIV birth .</brief_summary>
	<brief_title>Treatment With Combinations Several Antiviral Drugs Infants Young Children With HIV Infection</brief_title>
	<detailed_description>This study examine antiretroviral activity ZDV/3TC/NVP vertically-infected infant child age 15 day 2 year , ZDV/3TC/NVP/ABC vertically-infected infant child age 30 day 2 year . This study assess HIV-1 CD4/CD8 T-cell kinetics , activation , maturation . It also test concept early ( young 3 month age ) use potent , combination antiretroviral therapy allow long-term control viral replication preservation normal immune function . [ AS PER AMENDMENT 3/11/98 : This study also examine antiretroviral activity ZDV/3TC/NVP/NFV vertically infect infant child . ] This 2-part Phase I/II , open-label trial HIV-infected infant . Part A ass triple combination ZDV , 3TC , NVP . Four eight patient enrol age cohort ( Cohort 1 : least 15 day , 3 month ; Cohort 2 : 3 month , 2 year ) . Part B assess quadruple combination ZDV , 3TC , NVP , ABC . Eight patient enrol age cohort ( Cohort 3 : least 30 day , 3 month ; Cohort 4 : 3 month , 2 year ) . [ AS PER AMENDMENT 3/11/98 : This study 3-part Phase I/II trial . Parts A B . Part C ass quadruple regimen d4T , 3TC , NVP NFV . Up 8 patient enrolled age cohort ( Cohort 5 : least 15 day , 3 month ; Cohort 6 : 3 month , 2 year ) . If 3 4 patient either cohort Part B achieve plasma RNA le 1,000 copies/ml 16 week quadruple therapy , enrollment patient cohort stop enrollment 8 patient correspond cohort Part C begin . For Part C , patient whose RNA level 1,000 copies/ml Week 16 remain assigned treatment Week 104 . If time Weeks 16 104 patient 's RNA level increase great 1,000 copies/ml , plasma RNA repeat within 1 week . If RNA level great 1,000 copies/ml , patient discontinue study treatment follow every 12 week 1 year . ] [ AS PER AMENDMENT 4/14/99 : The study extend additional 96 week child continue suppression viral replication ( RNA le 400 copies/ml ) Week 104 . If time Week 12 16 Week 200 patient 's RNA level increase great 1,000 copies/ml , plasma RNA repeat within 1 week . If RNA level 1,000 copies/ml , patient discontinue treatment best available therapy follow every 12 week 1 year follow discontinuation study treatment . ] [ AS PER AMENDMENT 9/16/99 : An additional cohort ( Cohort 7 ) 5 10 patient add . Cohort 7 include patient 15 day 3 month age . Cohort 7 patient experience suppression viral replication Week 104 follow Week 200 . ]</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria Children may eligible study : Are 15 day 2 year old . Have consent parent legal guardian . Are HIVpositive . Exclusion Criteria Children eligible study : Have certain infection require treatment study . Have receive certain medication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Virus Replication</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>